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Cardiovascular disease (CVD) is the leading cause of death
and disability in most Western industrialized countries
including the U.S., cutting across all ethnic, racial, and
gender groups. Despite the tremendous body of research to
support the efficacy and cost-effectiveness of CVD preven-
tion, interventions to prevent CVD are universally under-
utilized. This section describes what is known about the
epidemiology of CVD, the distribution of CVD risk factors,
and the impact of treating CVD risk factors. The following
is a broad overview of the barriers to achieving CVD
risk-factor reduction and the measures that must be pursued
to enhance risk-factor reduction and CVD prevention.
Research, funding, and policy recommendations that would
improve CVD prevention, if embraced, will be provided.
EPIDEMIOLOGY OF CVD
Global burden. Cardiovascular disease includes common
conditions, such as coronary heart disease (CHD), stroke,
hypertension, and heart failure (HF), and those less com-
mon, such as congenital heart disease, cardiomyopathy, and
peripheral vascular disease (1). Cardiovascular disease is
increasing in prevalence in many regions of the world,
particularly in developing countries and in formerly socialist
countries (2). Worldwide, it is estimated that death from
CHD will increase 100% in men and 80% in women from
1990 to 2020, with the majority of that increase coming
from Asia, Africa, and Latin America (2). Similarly,
disability-adjusted life-years lost will increase 107% in men
and 74% in women worldwide (2).
The reasons for this epidemic are easily identifiable. The
20th century saw dramatic economic improvement, with
declines in major infectious diseases and malnutrition in
industrialized countries. Associated with a longer life span
and affluence has been the emergence of chronic diseases
that occur among those living past middle age. Changes that
were seen in the 20th century in industrialized countries are
now increasingly observed in the developing world. Tech-
nology and the expanding control over the environment
have resulted in abundant food supplies in many nations.
Industrialization of everyday life with laborsaving devices
and motor transportation results in a loss of regular physical
activity and the assumption of a sedentary lifestyle. The
combination of inactivity and surplus calories (particularly
from animal products) contributes to abnormal blood lipids
and elevated blood pressure (BP) and results in widespread
obesity, diabetes, and excessive risk of CVD. Inexpensive
machine-made cigarettes and the social acceptance of to-
bacco smoking result in widespread nicotine addiction and
the many chronic illnesses associated with tobacco. These
dramatic changes in the social and economic environment,
which are unparalleled in human history, are resulting in
massive elevations in both the risk and expression of CVD
(3).
Genetic influences. The transformation of the social en-
vironment, coupled with increased longevity, have un-
masked a genetic susceptibility to a number of chronic
diseases. Although it is very unlikely that evolution would
result in genes that promote lethal diseases, it is hypothe-
sized that so-called “thrifty genes” were adaptive in a
primitive world of deprivation and danger. The retention of
sodium, storing of food calories, and preparation for severe
stress were protective of humankind’s existence (3). How-
ever, in an aging society of affluence, such genes may
promote high BP, obesity, and maladaptive responses to
stress. The effect of the environment on genetic suscepti-
bility is best exemplified in evaluative studies of individuals
from low-risk, low-CVD cultures who migrate to Western
cultures, such as Japanese from Japan to California. The
low-risk Japanese become like their white neighbors in
disease-risk factors and expression when they assume their
high-risk environment and behaviors (4).
Gender. Cardiovascular diseases are manifest earlier in the
lives of men, and much of the focus of research has been on
this group. Although women manifest CVD 10 to 15 years
later than men, the overall morbidity and mortality over a
lifetime is similar in men and women (1). Many Americans
do not realize that CVD mortality for both men and women
is higher than mortality from all cancers combined. Women
are now appropriately recognized as frequent victims of
CVD; thus, programs oriented to the diagnosis and treat-
ment of CVD in women as well as men increasingly are
being emphasized in the U.S.
Racial and socioeconomic disparities. In a period of
epidemiological transition, chronic disease epidemics usu-
ally emerge first among economically advantaged segments
of society, and the burden is subsequently shifted to the
working class and minority populations (5,6). Cardiovascu-
lar disease represents one of the most dramatic examples of
this process. Not only has the overall rate of CVD changed
dramatically in the U.S. over the last 50 years, the distribu-
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tion of disease burden among sociodemographic subgroups
has changed as well. Although virtually every U.S. subpopu-
lation has experienced a decline in mortality from CHD, the
rate of decline has been much steeper among those of higher
socioeconomic status. National data by social class are
limited, because the required information was not collected
on death certificates until the 1990s. However, trends by
geographic and racial/ethnic categories confirm these grow-
ing disparities in CVD (7). Income inequality is correlated
with CVD incidence and may partially account for these
worsening trends (8). Black Americans now experience the
highest age-adjusted rates of heart disease, in addition to the
highest rates of stroke, as has been noted for many years (7).
Native Americans, Asians, and Hispanics, on the other
hand, currently have rates of both CHD and stroke that are
substantially lower than among the white majority popula-
tion (9), although the limited data that are available suggest
relative increases in rates of CVD among Native Americans.
Economically disadvantaged neighborhoods (10) and re-
gions of the country (e.g., Appalachia and the South)
experience higher rates of CVD (7). One of the most
extreme examples can be found among blacks in Mississippi,
in whom CHD rates are still rising in absolute terms, and a
very large gap has emerged in comparison to the majority
population. This heterogeneity in trends requires a broad-
ening of the definition of “high-risk.” Whereas the term
previously referred to individuals whose coronary profile put
them at increased risk of CVD, high-risk population sub-
groups can now be identified on the basis of sociodemo-
graphic profiles.
Temporal trends. Perhaps the most striking disease trend
in the U.S. during the 20th century was the rise of
age-adjusted CVD to a peak in the 1960s and a subsequent
decline. Similar, although somewhat delayed, patterns were
observed in much of Western Europe. In many of the
former socialist countries and the developing world, increas-
ing rates of CVD continued in the last part of the 20th
century (1,11).
There are other trends in CVD not readily apparent in
the overall age-adjusted data. For example, although age-
adjusted rates have declined steadily, absolute mortality (i.e.,
the total number of deaths) has changed little in the past
two decades (12,13). Cardiovascular diseases are still highly
prevalent but have been pushed into older age groups, a
trend obscured by age adjustment.
Also apparent in the mortality trend is the wide difference
between in-hospital and out-of-hospital mortality. Out-of-
hospital mortality accounts for approximately two-thirds of
all deaths from CHD (14). Whereas in the 1970s and early
1980s, in-hospital and out-of-hospital mortality fell in a
parallel fashion, more recent data from the late 1980s and
1990s found in-hospital mortality falling more rapidly.
Sudden, out-of-hospital death comprises an increasing pro-
portion of the mortality burden. This pattern, combined
with increasing rates of HF mortality and a gradual leveling
of stroke mortality, finds overall age-adjusted CVD mortal-
ity still falling, but more slowly than during the period from
1970 to 1990 (Fig. 1) (13). Finally, these trends are not
equally manifest in all ethnic groups, with the poor and
ethnic minorities manifesting less positive changes, as noted
earlier.
Many factors have been invoked to explain these trends.
In earlier years, better detection and treatment of hyperten-
sion contributed to declines in CHD, stroke, and HF
mortality. Similarly, falling levels of blood cholesterol asso-
ciated with improved dietary patterns influenced the ath-
erosclerotic diseases. Finally, cigarette smoking decreased,
dramatically influencing many diseases (15). However, in
Figure 1. CHD mortality trends by race and gender, U.S. 1979–1998. CHD  ICD-9 410–914, 429.2. Data source: CDC Wonder.
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the 1990s, risk factors did not decline at the same rate. In
fact, obesity and diabetes are increasing in the U.S. popu-
lation, and physical inactivity is common and is not improv-
ing. At the same time, medical care has advanced consid-
erably leading to improved survival (reduced case fatality) in
acute myocardial infarction (MI). While enhanced medical
care reduces mortality and prolongs survival, it adds to the
number of prevalent cases in need of secondary prevention.
These contrasting trends lead to both optimistic and
pessimistic inferences. On the one hand, the highly dynamic
nature of the trends demonstrates that broad interventions
aimed at CVD control can be highly effective. On the other
hand, the moderating decline and the fact that current
approaches apparently lack efficacy for many segments of
our society suggest that “more of the same” may not be
successful and that new interventions and implementation
strategies will be required.
CARDIOVASCULAR RISK FACTORS:
DISTRIBUTION AND IMPACT OF TREATMENT
Relationship of risk factors to major CVDs. Atheroscle-
rosis and hypertension are lifelong processes that result in
diseased arterial vessels that ultimately restrict blood flow,
reaching the clinical spectrum in late middle age. This
pathology is manifest as MI, stroke, congestive HF, periph-
eral vascular disease, and other conditions (Fig. 2). The
scientific understanding of the origins of this lifelong illness
and its etiologic mechanisms is substantial. To the classical
risk factors of hypertension, hypercholesterolemia, and cig-
arette smoking are added diabetes, obesity, and sedentary
lifestyle. Genetic factors play an important role in the
development of these risk factors (e.g., familial hypercho-
lesterolemia) and susceptibility to the progression to CVD.
A second level of risk factors associated with the atheroscle-
rotic lesions, more recently described, may play an impor-
tant role in combination with classic risk factors. Such
factors include inflammation, endothelial dysfunction, hy-
percoagulability, insulin resistance, and others. Finally,
acute risk factors may precipitate atherosclerotic plaque
rupture and be crucial in sudden out-of-hospital cardiac
death, acute MI, and stroke. Such factors include heavy
physical exertion, sexual activity, emotional stress, and
nicotine (16). Knowledge about the detection, treatment,
and control of risk factors provides the impetus and ratio-
nale for CVD prevention.
Global distribution of risk factors. The distribution of
risk factors in different parts of the world varies consider-
ably, resulting in high- and low-risk cultures. Key observa-
tions that led to the identification of classical CVD risk
factors have come from international comparisons such as
the Seven Countries Study (17). This study demonstrated
that differences in disease rates among the U.S., various
nations in Europe, and Japan were directly related to BP,
eating patterns, blood cholesterol, and cigarette smoking.
More recent comparisons with similar findings were found
in the Monitoring Trends and Determinants in Cardiovas-
cular Disease (MONICA) Study, which principally in-
cluded centers not only in Europe but also in North
America, Australia, and Asia (18).
Just as the global burden of CVD is great, the burden of
risk factors within geographic areas closely matches those
disease patterns. In addition to the substantial continuing
burden of CVD risk factors in Western industrialized
countries, there is an increasing burden of risk in other parts
of the world. Rich diets, obesity, sedentary lifestyle, ciga-
rette smoking, hypertension, elevated blood lipids, and
diabetes, common in the U.S., are increasingly observed in
developing nations. These observations underlie the con-
cerns about a coming global epidemic (3).
Age. The major CVDs are conditions associated with gains
in life span (e.g., atherosclerotic lesions increase with
advancing age). While 19% of all deaths in the 35- to
Figure 2. Risk factors. LVH  left ventricular hypertrophy; MI  myocardial infarction; PVD  peripheral vascular disease.
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44-year-old age category are due to CVD , 53% of deaths
are CVD-related by age 85 years (13). This age–disease
relationship is consistent across genders and ethnic groups
in the U.S. (1). The prevalence of classic risk factors of
blood cholesterol and cigarette smoking in the population
declines with age. For example, smoking rates are under
10% for those over age 84 (19). The decline in smoking with
advancing age is partially due to smoking cessation in the
elderly and to selective attrition as those at highest risk
succumb to the disease. Systolic BP climbs with age,
presumably as a result of increasingly noncompliant blood
vessels, and continues to carry increased risk. Although the
average prevalence and relative risk of risk factors are lower
in the older adult group, blood lipids, cigarette smoking,
and hypertension remain predictive of mortal and morbid
outcomes, and the absolute risk of these risk factors is
greater, resulting in an enormous burden in the older adult
population (20).
The crucial importance of aging as a risk factor for CVD
relates in part to the aging of the population. In 2000, the
U.S. life expectancy at birth achieved a new high of 76.9
years (21), up almost 30 years from 1900, when life
expectancy was 47 years. It is estimated that currently one in
every eight Americans is age 65 years or older; a number
expected to increase to one in five by 2030 (22). Because the
incidence of CVD, such as HF, MI, atrial fibrillation, and
stroke, increases dramatically with advancing age, CVD will
place an increasing burden on the health care system in the
new millennium.
Gender. Cardiovascular (CV) risk factors differ by gender,
as does their treatment. Mean blood cholesterol levels are
higher in men than in women until the sixth decade, and
higher in women after that (14). Women are less likely to be
treated for elevated blood cholesterol than men (23). Blood
pressure and the prevalence of hypertension are higher in
men than in women across the age spectrum, though the
differences narrow in the elderly. However, high BP is more
likely to be detected, treated, and controlled among women
(24). Rates of smoking in the U.S. and most Western
industrialized nations were higher in men than in women
for many years, but women have lagged behind men in the
decline in smoking prevalence. Hence, the gap between
male and female smoking rates has narrowed (25). Although
there are differences, other major risk factors, including
obesity and diabetes, are high and increasing for men and
women.
Ethnicity and socioeconomic status. As is well known, a
fundamental racial/ethnic differential for BP is found in the
U.S., with twofold excess of hypertension among black
Americans. Mean blood pressures are approximately 5 mm
Hg higher in the adult black population; treatment and
control rates are currently somewhat better for whites than
blacks (26). As in the past, this differential accounts for
some of the excessive CVD mortality. Among Mexican
Americans, hypertension rates are similar to whites; how-
ever, the rate of detection, treatment, and control is low.
Among men in this ethnic group, for example, only 11% of
those with hypertension are controlled, compared with a
national average of 28% (27).
Racial and economic disparities in cigarette smoking also
have been observed. Native Americans have the highest
rates of cigarette use, whereas Asian and Hispanic women
have the lowest. Tobacco use declined through the early
1990s and appears to have leveled at 25% of the population
(7). Further declines appear to have slowed for all ethnic
groups. The greatest declines have been among persons with
a college education.
White and black Americans have similar levels of total
serum cholesterol, although blacks—particularly black
men—have higher levels of high-density lipoprotein cho-
lesterol and lower triglycerides (28). Other U.S. ethnic
groups have usually been found to have lower cholesterol. A
positive social class gradient (i.e., lowest levels among
persons with the least educational or occupational attain-
ment) was observed in surveys in the 1960s; however, by
1990 that gradient had been reversed.
Among the most important emerging differentials in
CVD risk is that observed for obesity and diabetes (26). A
sharp social class gradient exists for obesity, especially
among women, and is associated with a similar pattern for
type II diabetes. All the major ethnic subpopulations in the
U.S., with the exception of Chinese and Japanese, have
twofold greater prevalence of diabetes than do whites.
Temporal trends: risk factors are changing in the U.S.
population. Risk factors in the U.S. population continue to
change in a complex pattern. Currently, within the U.S.,
elevated risk factors are quite common, with hypertension
affecting 25%, hypercholesterolemia 20% to 50%, and cig-
arette smoking 25% of the adult population. The classic risk
factors consistently improved through the 1970s and 1980s.
Perhaps the most outstanding success story is that of
cigarette smoking. Cigarette consumption per capita for
individuals age 18 years and older rose steadily from 1900
through the late 1960s. Since that time, it has steadily
declined, though in recent years that decline has been slower
(29). The National Health Interview Survey found that
37.6% of adult men smoked in 1980 and 28.4% in 1990.
Similar declines were noted among women. However, there
is significant variability by region of the country. In 1999,
the percentage of adults who smoked ranged from a high of
29.7% in Kentucky to a low of 13.9% in Utah (30). In states
such as California and Massachusetts, where increased taxes
have been used for tobacco education and research, some of
the lowest smoking rates (18.7% and 19.4%, respectively)
have been observed.
Similar to cigarette smoking, there was a consistent fall in
elevated blood cholesterol and hypertension between the
Second National Health and Nutrition Examination Survey
(NHANES II) (1976 to 1980) and the Third National
Health and Nutrition Examination Survey (NHANES III)
(1988 to 1991) studies. Between NHANES II and
NHANES III, the prevalence of hypertension fell 42.5% in
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men and 38.9% in women (31). These data, while some-
what inaccurate because of differing measurement method-
ologies, are observed in other population studies (32). In
addition, blood cholesterol above 240 mg/dl (greater or
equal to 6.2 mmol/L) dropped 28.9% in men and 27.6%
among women, and the mean cholesterol in adults de-
creased from 220 mg/dl to 205 mg/dl in the same period.
This striking difference results largely from dietary changes
in the population, as few individuals during this period were
under treatment with cholesterol-lowering medications
(14). However, more recent data suggest that despite the
availability of more effective pharmacologic treatment
methods, blood cholesterol in the population is no longer
falling (23).
Likewise, leisure time physical inactivity has not declined
in recent years (33). Approximately 25% of Americans age
18 and older report no leisure-time physical activity, and
only 23% of American adults report vigorous sustained
physical activity of any intensity lasting 30 min or more five
times a week. The majority of Americans fail to reach the
recommended amount of physical activity. Inactivity is more
prevalent among women than men, among blacks and
Hispanics than whites, and among older than younger
adults (34). Physical inactivity is closely related to obesity,
hypertension, and unfavorable lipid levels.
Finally, other risk factors are moving in the opposite,
unhealthy direction. The population is gaining weight at an
alarming rate. The prevalence of obesity (body mass index
greater than 30 kg/m2) increased 61.8% in men and 50.9%
in women between NHANES II and NHANES III (35).
Increasing obesity affects both genders and all race groups
but is particularly marked in black women (26). Associated
with increasing obesity is type II diabetes, which is also
increasing in the population (1). Diabetics also frequently
have hypertension, hyperlipidemia, and other conditions
that add to their risk of CVD. The Framingham Study
found that diabetics have double the age-adjusted CVD risk
in men and triple in women compared with non-diabetics
(1,36).
In summary, the prevalence of CV risk factors is chang-
ing. Although some of these changes are in a favorable
direction, such as cigarette smoking, cholesterol, and BP,
the majority of other risk factors in the 21st century are not
showing similar trends. The loss of momentum is a cause for
concern.
CVD PREVENTION
Primordial prevention with health promotion. Consid-
erable progress in the primary and secondary prevention of
CVD has occurred in the past 30 years. Risk factors are
identified and treated in those not yet ill (primary preven-
tion) and among those with established CVD to prevent
recurrent events (secondary prevention). It is time to con-
sider whether elevated risk factors are, in fact, necessary and
inevitable. Should we consider primordial prevention (i.e.,
the prevention of risk factors) in the first place? This may be
the only viable strategy if ultimately we are to eliminate
these diseases and expand the achievements of primary and
secondary prevention (Fig. 3).
The predominant focus on the manifest-disease end of
the spectrum of risk factors may have inadvertently robbed
the community of opportunities for prevention. Although
the development of risk-factor thresholds (e.g., hyperten-
sion being defined as a BP greater than 140/90 mm Hg,
systolic and diastolic, respectively) has helped patients and
clinicians focus on treatment objectives, such cut points
have obscured the continuum of risk. Normal levels are
inappropriately assumed to be desirable. For instance, BP
levels considered by most clinicians and patients to be
“normal” (systolic pressure of 130 to 139 mm Hg, or
diastolic pressure of 85 to 89 mm Hg, or both) are
associated with a risk-factors-adjusted hazard for CVD of
2.5 in women and 1.6 in men (37).
If studies of individuals at the healthiest end of the
Figure 3. Cardiovascular disease prevention opportunities. ACE-I  angiotensin converting enzyme inhibitor; ASA  aspirin.
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risk-factor spectrum are examined, successful primordial
prevention would shift the population distribution to a
higher prevalence of individuals with optimal risk factors.
Such a shift would end the CVD epidemic and would
significantly extend life expectancy (38–41). The definition
of “optimal” or “low risk” varies somewhat from study to
study but generally includes a combination of having low
cholesterol (less than 200 mg/dl), low BP (less than or equal
to 120/80 mm Hg), desirable body weight (body mass index
is less than 25 kg/m2), no current smoking, and an absence
of diabetes and prior CVD. Currently, the percentage of
individuals in the U.S. and Europe with low risk-factor
profiles is low, on the order of 3% to 10%. (38,39). Of note,
individuals with low-risk profiles have markedly better
prognoses, with an 80 to 90% decrease in coronary events
and CVD mortality (38,39) and an estimated gain in life
span of 6 to 10 years (38).
Progress toward the goal of primordial prevention has
achieved mixed results. For most risk factors (e.g., high
cholesterol) a basis for action exists, effective results have
been demonstrated in trials, and reductions in cholesterol
have been observed in the population. The Dietary Ap-
proaches to Stop Hypertension study has demonstrated that
nutritional intervention reduces high-normal BP and cho-
lesterol in adults (42). Observational data from the Nurses’
Health Study suggests that 91% of cases of diabetes were
associated with unhealthy behaviors and habits (43). A
recent trial from Finland testing the efficacy of moderate
weight loss and exercise (44), and data from the larger
Diabetes Prevention Program clinical trial examining diet
and exercise, demonstrate that diet and exercise significantly
lower the risk of diabetes (45). Hence, the available evidence
supports recommendations for exercise and for healthy
eating patterns (low sodium, low saturated fat, low choles-
terol, and high intake of fruits and vegetables), to prevent a
number of chronic diseases.
Is primordial prevention feasible? A primordial preven-
tion strategy will require a very different approach from the
current high-risk strategies. The campaign will need to
confront many of the social, cultural, and community
aspects of elevated risk. Primordial prevention will require a
focus on youth and a particular emphasis on exercise and
diet (minimizing fat, calories, and sodium) (46). There are
data on the positive effects of programs beginning in youth,
though further research is clearly needed (47–49). Healthy
communities and healthy societies should be the goal.
While risk factors in the U.S. track from childhood, there
are many societies in the world that do not have a progres-
sive elevation of BP with age and do not increase their lipids
after adolescence. In these societies, physical activity and
healthy diets are the norm, and CVD does not occur at
epidemic levels. Such is the hope, promise, and challenge of
primordial prevention of CVD.
Primary prevention. The undeniable health and survival
benefits of optimizing of CVD risk factors have been
documented by numerous observational and randomized
controlled trials and have been incorporated into widely
disseminated guidelines (50,51). Meta-analyses and cost–
benefit analyses (reviewed in depth in Task Force 2) of BP
reduction (52), cholesterol lowering (53,54), increased phys-
ical activity (55), glucose control in diabetics (56), weight
loss among obese individuals (57), and smoking cessation
(58,59) reveal significant reductions in a wide variety of
CVD end points (including MI and stroke), health care
expenditures, and death.
Evaluating the individual’s global risk is essential in
gauging the intensity of intervention, as has been high-
lighted by a previous Bethesda Conference (60). Until
recently, practitioners and professional societies have fo-
cused on treating individual risk factors in treatment plans
and practice guidelines. However, risk factors frequently
cluster in the individual, and risk escalates dramatically with
the accumulation of risk factors (61). This is particularly
true of patients affected by the metabolic syndrome, wherein
insulin resistance is accompanied by obesity, hypertension,
and an unfavorable lipid profile (62). The presence of
diabetes is now understood to confer equivalent risk on
established CVD (63), and hence recent guidelines empha-
size that subjects with diabetes are appropriately treated
with secondary prevention thresholds developed for patients
with prior CVD events (64). Despite the rapid growth in
scientific knowledge, as previously described, evidence sug-
gests that the decline in most risk factors seen from 1970 to
the 1990s has either slowed or stopped. A number of factors
may be responsible. The segments of the population that are
most willing to adopt preventive recommendations have
been reached. Remaining obstacles are often deeply embed-
ded in the structure of our society—for example, the high
salt content of processed food and the lack of opportunity to
maintain an active lifestyle in many communities. Regaining
the momentum in primary prevention will require wide-
spread policy changes and education.
Primary prevention encompasses strategies to prevent
clinical events after the development of risk factors that
require drug treatment. Unless we effectively implement
primordial prevention, 21st century public health may have
to incorporate lifelong “pill taking” among those at high
risk. As we develop new policy directions in primary
prevention, the magnitude of the challenge to control risk
factors in those who have already developed them is becom-
ing better recognized. In the U.S. the prevalence of hyper-
tension is 25%, and 18% of the population meets the new
criteria for drug treatment of hypercholesterolemia (65). To
reach this large a segment of the population, new ap-
proaches to detection, drug distribution, and strategies to
maintain adherence will be required.
Secondary prevention. The implementation of preventive
therapies after a clinical event or manifestation of an
underlying atherosclerotic process, termed “secondary pre-
vention,” has received increased attention and emphasis
during the past decade. This emphasis on secondary pre-
vention has been attributable largely to the increase in
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survival resulting from an improved treatment of patients
presenting with acute coronary syndromes and the emer-
gence of several landmark studies demonstrating the efficacy
of preventive interventions in reducing subsequent mortality
and morbidity in this patient population.
Patients with established CVD are at high risk for future
events and therefore merit the implementation of aggressive
secondary prevention therapies (65,66). Sudden death is 4 to
6 times more frequent among survivors of MI than in the
normal population. Patients who survive MI until discharge
have a one-year mortality rate as high as 26% to 36% if they
have moderate or severely decreased left ventricular systolic
dysfunction and clinical or radiographic signs of HF during
hospitalization (67). Increasing numbers of patients are
being diagnosed and hospitalized with CHD. From 1979 to
1998, hospital discharges for CHD increased 24.5% for men
and 26.4% for women (1).
The American Heart Association (AHA), American
College of Cardiology (ACC), and other professional and
governmental organizations have endorsed secondary pre-
vention interventions through the formulation of guidelines,
which should be widely used for the secondary prevention of
atherosclerotic CVD (66,68). These recommendations gen-
erally include: 1) smoking cessation; 2) BP control to a goal
of less than 140/90 mm Hg (or lower with co-morbidity); 3)
management of dyslipidemia to a target low-density li-
poprotein cholesterol level less than 100 mg/dl using dietary
measures and lipid-lowering therapy; 4) regular exercise; 5)
weight management; 6) diabetes management; 7)
angiotensin-converting enzyme inhibitor therapy (ACE-I),
especially for those with depressed ventricular function; 8)
antiplatelet therapy; and 9) beta-blocker therapy. Similar
guidelines for the treatment of HF have also been developed
(69). The evidence-based support for these recommenda-
tions is compelling. Most of the interventions are associated
with reductions of 20% to 30% in total mortality, similar
reductions in recurrent CV events including stroke, and the
need for revascularization procedures (70). Adherence to the
treatment guidelines is also associated with improved quality
of life (71).
Unfortunately, secondary prevention therapies are not
fully implemented. Studies from the Health Care Financing
Agency (now called Centers for Medicare and Medicaid
Services) and several large registries indicate that on average,
among ideal candidates, appropriate treatment is received by
less than 25% for lipid-lowering therapy, less than 25% for
smoking cessation, and less than 65% for ACE-I and
beta-blockers (72–74). A recently published study from the
NHANES III database suggests that among survivors of
stroke or MI almost half of the subjects with hypertension,
hypercholesterolemia, and diabetes have inadequate risk-
factor control (75). There is significant regional variation in
the U.S. in the use of secondary prevention therapies; with
the greatest implementation generally in the Northeast and
the lowest in the Southeast. There is also reported lower use
of secondary prevention therapies among the elderly (73,76)
and certain ethnic groups, particularly black Americans (75).
Of concern is the low utilization of cardiac rehabilitation
programs nationwide, estimated to be less than 20%, which
offer the potential for support of secondary prevention
therapies. Similar to other preventive modalities, cardiac
rehabilitation programs are disproportionately underutilized
by the elderly, women, minorities, and those living in the
southern U.S. (77). It is important to recognize that lack of
insurance coverage may contribute to underutilization of
cardiac rehabilitation.
Studies using hospital-based secondary prevention treat-
ments have been initiated by several groups including the
AHA and the ACC. The initial results from these programs
suggest that significant improvement in treatment rates,
which are associated with reductions in one-year mortality,
can be achieved (78,79). In addition, analyses of the
economic benefits suggest that the implementation of sec-
ondary prevention treatments would be cost-effective com-
pared with standard high-technology approaches (see Task
Force #2) (80,81).
BARRIERS TO ACHIEVING RISK-FACTOR REDUCTION
Community and societal barriers to the prevention of
CVD. The fundamental contribution of lifestyle behaviors
to the prevention and reduction of risk factors, and the high
prevalence of risk factors in most population groups, man-
date a public health approach to preventing CVD.
Community-wide as well as clinical strategies must be
employed in an effort to reduce both individual and popu-
lation risk.
As reviewed in depth by Task Force #3, research has
demonstrated that interventions to date have increased
knowledge, changed lifestyle behaviors, and improved risk
factors. However, CVD morbidity and mortality in the
intervention communities did not exceed the gains observed
in control communities (82). Only one of the six community
CVD Prevention studies (83–89), the Franklin Cardiovas-
cular Health Program, has demonstrated a reduction in
mortality. It is possible that secular trends were shifting the
population distribution of risk factors during these years.
Confounding changes, such as the rise in obesity, may have
blunted the effect of the interventions. Furthermore, none of
these studies had the statistical power necessary to examine
subgroup differences that might illustrate significant effects
of the interventions. It may be that study designs other than
clinical trials, which evaluate the effects of more intensive
interventions or interventions delivered over longer periods
of time, would result in more encouraging results.
Despite the difficulties of effective intervention, the im-
portance of community, socioeconomic, and environmental
barriers to risk reduction has been demonstrated by numer-
ous studies (90). In Harlem, a survey was conducted to
examine the prevalence and social correlates of CVD (91). A
high prevalence of major risk factors and the presence of
multiple risk factors were observed. Income and education
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were inversely related to hypertension, smoking, and phys-
ical inactivity. Having three or more risk factors was
associated with low income, low education, and a history of
unstable work or homelessness.
Recently, the National Heart, Lung, and Blood Institute
(NHLBI) as part of a Request for Application (RFA)
targeting underserved minorities, funded several studies
examining community-based hypertension programs and
the extent to which they are linked to clinical care. A clinical
trial in Seattle assessed the effectiveness of enhanced track-
ing and follow-up services provided by community health
workers in promoting medical follow-up of persons whose
elevated BP was detected at community sites. The enhanced
community health worker intervention increased medical
follow-up by 39% (92). Ward et al. (93) in Los Angeles are
conducting a clinic- and community-based study of hyper-
tension control focusing on environmental and psychologi-
cal factors related to treatment adherence. The investigators
are examining the effects of three interventions: individual-
ized counseling sessions, home visits/discussion groups, and
a computerized appointment-tracking system to evaluate
how to most effectively enhance adherence to hypertension
treatment. Studies of this nature will provide valuable
insights into patient adherence.
Community-based studies have contributed to our un-
derstanding of the importance of the environmental, social,
and cultural context of individuals’ CV risk. Environmental
stressors and accepted cultural “norms” may be barriers to
achieving CV risk reduction and must therefore be identi-
fied and addressed to realize the reductions. Similarly, an
understanding of changes in cultural norms (e.g., increased
hours and pace of work, decreasing leisure time, and
increased consumption of fast food) will inform
community-level strategies to reduce risk. The variation in
the composition of subgroups of individuals who respond to
various aspects of community CVD interventions illustrates
the necessity for the development and evaluation of inter-
ventions that are targeted to specific age, socioeconomic,
and cultural subgroups.
Numerous studies in community settings, such as the
work site, show that it is possible to increase access,
convenience, and continuity of care and to reduce the cost of
preventive health care for eligible individuals. However,
over time, even in fully insured health workers receiving free
medication, BP control rates averaged only 12% (94). As
Alderman (95) suggested, “Blood pressure treatment is
preventive medicine and it may not mix well with sick care,
which is what the American medical care system is about.”
Inequities in health status have long been associated with
education, poverty, inadequate housing, unemployment,
lack of health insurance, racism, and gender barriers (96).
The gap in income in the U.S. between those well above and
well below the poverty line continues to widen, and the
disproportionate prevalence of risk factors and receipt of
medical services among racial and ethnic groups across the
income continuum persists (97). Health providers’ lack of
understanding, stereotypical perceptions, and insensitive
communication pose major challenges in practice and re-
search among our increasingly diverse population (98).
Social, economic, and environmental risk factors, as well as
individual differences in risk factors, and community partic-
ipation in the design and conduct of studies need to be
major foci of community-based research.
Medical setting barriers. There is a disappointing discrep-
ancy between the efficacy of treatments in randomized trials
and their effectiveness in clinical practice (99). For many
years, the onus for the gap between the expectations for
CVD prevention and the reality of practice was placed on
the patient’s “failing to follow doctor’s orders” (100). How-
ever, virtually every study of preventive therapies, including
hypertension control, smoking cessation and cholesterol
lowering, has demonstrated that physicians have not pur-
sued the goals of prevention outlined in widely disseminated
guidelines. It is tempting to blame individual physicians as
lacking the knowledge or the motivation to effectively
implement preventive practices. However, marked gaps
between risk-factor reduction goals and achieved results
have been documented in a broad range of medical settings
throughout the developed world, including nations with
national health care systems (101,102). Thus, increasingly,
experts have looked to the health care system to explain the
lack of adherence to prevention guidelines. The systemic
barriers include a complex weave of attitudinal, knowledge,
and systemic limitations (Fig. 4) (103).
The attitudinal barriers in the medical system involve
both priorities and beliefs (as reviewed in depth by Task
Force #5). The emphasis in medical school and training is
on diagnosing and treating acute illness. Physicians receive
very little education in prevention and the management of
chronic conditions (104). Cardiologists, in particular, often
view their role as managing the acute event; they frequently
defer long-term prevention issues to primary care providers.
But the lack of specialist attention reinforces the perception
on the part of primary care providers and patients that the
treatment of chronic risk factors and lifestyle modification
are discretionary practices (104,105). Another barrier for
physicians is their perception of their role as teachers rather
than as facilitators of medical treatments. The difference in
responsibilities is captured in the very language we use to
describe the failure of patients to follow advice and take
medications. The term “compliance” implies a passive role
for patients, rather than more contemporary terms such as
concordance or adherence, which emphasize interactive
problem solving between patients and doctors to achieve the
desired end—risk-factor modification (adherence is also
reviewed in the Task Force #4 report) (106,107). Still
another belief, referred to as “poor outcome expectancy,”
that acts as a barrier to improving risk factors in the public
is the ubiquitous perception that counseling about lifestyle
modification, such as smoking, is ineffective (108), despite
published studies to the contrary (109).
Part of the gap in risk-factor reduction may be the result
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of knowledge deficits. The quantity of accumulated observa-
tional and randomized studies linking a multitude of risk
factors to CVD is staggering; it is increasingly difficult for
the busy clinician to “keep up” with the literature in any area
of medicine. Professional societies and experts have looked
to guidelines to summarize the existing literature and provide
the clinician with direction in best practices. Unfortunately,
there is an extensive literature on the failure of guidelines to
live up to expectations, highlighting attitudes, knowledge,
and behavior as barriers to implementation (103). Attitudi-
nal barriers, alluded to earlier, include a lack of outcome
expectancy, lack of self-efficacy, and lack of motivation
(103). Many physicians resent the rigidity of guidelines and
the attendant loss in autonomy (110) because they misun-
derstand the concept of guidelines. Guidelines are not
intended as rigid rules but rather as an evidence-based
framework within which clinicians should exercise their
judgment. Others have raised concerns about the scientific
rigor and independence of guidelines (111). A lack of
knowledge of the content of guidelines constitutes another
barrier to their implementation. In one study, 41% of
physicians were unaware of or unfamiliar with, the Joint
National Committee Guidelines on the Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure,
and this lack of familiarity translated into less adherence to
the Guidelines’ recommendations (112). The lack of famil-
iarity with a specific set of guidelines is not surprising, as it
has been estimated that general practitioners have as many
as 25 guidelines to follow on a wide range of medical
conditions (113). Disagreement among guidelines, which
sometimes conflict in their assessment of risk and their
recommendations, has also been a deterrent to their imple-
mentation (114,115).
The plethora of available guidelines—which have focused
on the relative risk of specific risk factors rather than on
absolute risk of CHD given the presence of several risk
factors in an individual patient—has also contributed to
confusion (116). The physician and patient may feel over-
whelmed as to how to prioritize risk factor reduction in a
realistic and cost-effective manner. Health care providers
need to understand and be able to communicate what the
anticipated absolute benefit of a given risk-factor reduction
strategy is in a specific patient. Recognizing the importance
of these barriers, the ACC and the AHA have endorsed
consensus guideline statements for the primary and second-
ary prevention of atherosclerotic CVD. As discussed later in
this report, the secondary prevention guidelines have been
successfully incorporated into the ACC Guidelines Applied
in Practice project (www.acc.org/home_links/gap.htm)
(117) and the AHA Get with the Guidelines program.
Health care provider compliance with, and utilization of,
secondary prevention therapies has risen dramatically in
hospitals where these programs have been implemented.
The other major knowledge deficit for most providers is
in techniques for enhancing adherence to medication and
lifestyle changes. Although 95% of medical schools cur-
rently instruct students in communication skills (118), these
skills are rarely reinforced in postgraduate training and
continuing medical education programs. There is a large
body of literature in health social psychology that provides
insights into effective health counseling techniques (106).
However, most physicians have little exposure to current
theories in health psychology and effective counseling in
health behavior change, such as the 4As (ask about the
problem, advise with clear recommendations about desired
behavior change, assist in problem solving to overcome
barriers to behavior change, arrange follow-up) (118).
Hence, most physicians lack confidence in their ability to
enhance their patients’ adherence to medication and
behavior-change regimens (100).
Finally, there are profound systemic and organizational
barriers to the optimal implementation of risk-factor mod-
ification in clinical practice. The lack of clinician knowledge
in effective adherence techniques stems in part from a lack
of research on the subject. There has been an emphasis on
technology and treatment, with comparatively little atten-
Figure 4. Practice guidelines—barriers to adherence. Modified with permission from Cabana MD, et al. Why don’t physicians follow clinical practice
guidelines? A framework for improvement. JAMA 1999;282:1458–65.
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tion to factors that enhance adherence to recommended
treatments. For instance, there have been few randomized
controlled trials with adherence as the outcome—and even
fewer that have focused on techniques to increase long-term
adherence (119,120). Reviews of treatment-adherence stud-
ies reveal that many are methodologically flawed, prohibit-
ing firm recommendations on how to improve adherence
(121). Fortunately, recent grants from the NHLBI are
beginning to address the deficits in research on physician
compliance with guidelines, by researching minority and
low socioeconomic status patients’ adherence to risk-factor
intervention (e.g., http://grants.nih.gov/grants/guide/rfa-
files/RFA-HL-01-005.html).
Fundamentally, preventive services and risk-factor mod-
ification have not been given high priority by health care
organizations and third-party payors, either public or pri-
vate. For instance, Medicare and many insurance companies
do not reimburse for preventive screening, medications, or
cardiac rehabilitation (e.g., for patients with HF or coronary
artery disease not immediately post-MI). Individual physi-
cians are offered little incentive and organizational support
to pursue prevention in their practices. Preventive services
require time and effective communication, which often is
not reimbursed, and which competes with addressing the
immediate problems of patients (119).
Patient-related barriers to CVD prevention. The risk
status of individuals without CVD varies greatly, and this
variability mandates a range in the type, frequency, and
intensity of intervention (60). The Framingham Heart
Study and other studies have demonstrated that the major
risk factors for CVD are multiplicative in predictive power,
and many epidemiologic studies have identified a high
prevalence of multiple risk factors within individuals
(62,122). Cardiovascular disease intervention programs in-
creasingly target multiple risk factors. Successful risk-factor
reduction requires a targeted approach, with consideration
given to individual barriers to modifying major independent
risk factors prevalent in both symptomatic and asymptom-
atic individuals.
A recent review of the hypertension literature revealed
numerous patient barriers, including deficient knowledge
about the severity and controllability of risk factors, a lack of
health insurance or a primary care provider, economic
constraints to cover the cost of medication, and challenges
to adhering to a complex lifestyle and medication regimen
(100). These and other barriers, such as lack of confidence
in one’s ability to control risk factors, perceptions that the
benefits of risk reduction do not exceed the risks associated
with control of the risk factors, and competing priorities in
patients’ lives, make it difficult for some patients to commit
to achieving risk-factor control and to actively engage in
care.
The National Council on Aging conducted a national
survey in January 2000 comprising 1,500 persons age 50 and
older. The Council reported the following findings from
telephone interviews: 46% believed that a stressful life
causes high BP; 51% did not recognize kidney failure as a
consequence of untreated hypertension; nearly half (45%)
did not know their recent BP numbers, yet 80% had had
their BP checked within the past four months; and surpris-
ingly, 69% of the men and women surveyed had not
discussed the health consequences of high BP with their
health care providers in the past year (http://www.ncoa.org/
news/hypertension/hypertension.html). The results of this
study highlight the prevalence of inadequate knowledge
about risk factors.
One potential explanation for the lack of information
about the assessment of patient barriers, other than lack of
knowledge and insurance, is the inattention to myths about
coronary artery disease. Jan Breslow, MD, PhD, high-
lighted these myths, during his 1996 to 1997 presidency of
the American Heart Association as follows: 1) heart disease
is going away; 2) living with heart disease is not so bad; 3)
heart disease is a good way to die; 4) only older people have
strokes; 5) women do not get heart disease; and 6) no more
research is needed. Little is known about the extent to
which myths such as these influence patients’ prevention-
related to behavior. The influence of myths on patient
behavior and the effect of dispelling myths are important
areas for study.
APPROACHES TO BARRIERS IN CVD PREVENTION
A number of approaches to the barriers outlined in this
report have been identified and will be reviewed in depth by
Task Forces #3, #4, and #5. While there is overlap, the
proposed solutions can be analyzed as addressing knowledge,
attitudes, and structural barriers in the community, in the
medical setting, and at the patient level.
In the case of preventive CV medicine, advances in
knowledge have been incorporated into guidelines. Critiques
of guidelines have emphasized that guidelines must be
straightforward, concise, multidisciplinary, and evidence-
based. The goal is to develop guidelines that provide
clinicians with a rapid understanding of the strength of the
research supporting the guideline, the desired treatment
goal, and the relevance and anticipated benefit of risk-factor
treatment to the specific patient (111,113,123). To this end,
computerized risk-factor assessment tools have been devel-
oped (including a Personal Digital Assistant version avail-
able at http://www.statcoder.com/cardiac.htm) (122,124).
Similarly, the consolidation of primary and secondary pre-
vention guidelines for multiple cardiac risk factors into one
guideline by the AHA and the ACC is useful (50,66,68).
There is a great deal known about specific risk factors and
efficacious treatment, but research must address the major
scientific deficits in our understanding of how to improve
both provider and patient long-term adherence to preven-
tive treatments and lifestyle modifications.
To change provider attitudes about prevention, organiza-
tions have pursued strategies of increasing incentives for
risk-factor achievement, in part by using professional soci-
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eties and opinion leaders to promulgate the prevention
message, and in part through quality improvement activi-
ties. The National Committee for Quality Assurance is a
voluntary accreditation program with participation of 48%
of the nation’s 650 medical care organizations. The Health
Plan Employer and Data Information Set (HEDIS) has
begun to require health plans to report the percentage of
hypertensive patients who achieve BP levels less than
140/90 mm Hg and the percentage of patients who achieve
low-density lipoprotein cholesterol levels less than 130
mg/dl within one year after CV events (http://
www.ncqa.org/Programs/HEDIS/) (125). Twenty-seven
U.S. medical care organizations have developed a CHD
outcomes management program that follows the quality
improvement model of assessing the baseline condition and
strategizing for improvement (phase 1), intervening (phase
2), and subsequent follow-up assessment and modification
(phase 3). As noted by the investigators, these programs
provide several incentives to medical care organizations—
the potential to reduce case management costs, improve
patient care, and enhance perceived value to potential plan
purchasers (125). Similar primary and secondary prevention
projects following the quality improvement model have
been pursued in Texas. The model of empowering site-
specific problem solving for quality improvement has been
demonstrated to improve adherence to guidelines (126,127).
There have been several organizational interventions de-
signed to enhance the adherence of medical organizations to
risk-factor modification. To overcome barriers to adherence
will require adequate reimbursement for preventive activities
as well as modification of practice settings to implement
technological and health care team approaches to enhancing
risk-factor control. Examples of an organizational approach
to improving risk-factor modification, involving quality
improvement activities that provide direct feedback on
preventive medicine outcomes to plans and providers, are
the HEDIS and Texas projects described earlier. In addi-
tion, there is increasing evidence that computer software can
enhance clinical performance in assessing CV risk and
implementing preventive care by providing accurate assess-
ments of risks and reminders of desired treatment goals
(128,129). Critical pathways (management algorithms that
specify the sequence and timing of optimal treatment) (130)
and initiation of preventive treatment before hospital dis-
charge for an acute coronary event can also improve the
utilization of preventive therapy. Acknowledging the im-
portance of critical pathways and hospital initiation of
treatment, the AHA has launched a national program with
web-based resources (http://www.americanheart.org/
getwiththeguidelines/) to encourage acute care hospitals to
“Get with the Guidelines” for secondary prevention. Case
management systems integrating the services of a variety of
CV specialists, including physicians, nurses, and nutrition-
ists, have also improved adherence to preventive treatments
(131). Yet another structural mechanism for improving the
delivery of preventive cardiology is achieved by ensuring that
patients have adequate benefit coverage and that providers
receive appropriate remuneration for preventive cardiology
activities (132).
As noted throughout this report, despite the proliferation
of guidelines, the wealth of medications, and the increase in
knowledge about the benefits of risk-factor reduction, stud-
ies have demonstrated a leveling off, and in some instances
an increase in CV risk factors in the U.S. A tremendous
amount of money and effort continues to be devoted to
finding increasingly effective drugs. However, at least one
analysis of hypertension drugs suggested that improving
treatment compliance would create the highest gain in
cost-effectiveness and efficiency (133). Some have suggested
a departure from standard approaches to prevention. Ex-
perts have provocatively suggested that the same marketing
strategies aggressively and strategically employed by to-
bacco, pharmaceutical, and advertising companies be used in
medical education for professionals and to educate our
patients and the public (106,134).
Patient factors influencing CV health have been concep-
tualized as predisposing, enabling, and reinforcing by Green
and Kreuter (135) (Fig. 5). This approach integrates health
education, behavioral change and maintenance principles,
culturally sensitive strategies, social action, and social learn-
ing theory. This conceptual approach also allows for the
incorporation of economic, psychosocial, and behavioral
factors as antecedents to behavior change. Patients’ knowl-
edge, beliefs, values, and attitudes provide the rationale or
motivation for the healthy behavior. Enabling factors allow
a predisposition to be translated into behavior, such as
accessing health care resources or acquiring appropriate
skills. Reinforcing factors—such as family, peer, or health
care provider support—and supportive social services pro-
vide continuing support, reward, or incentives, reinforcing
maintenance of healthy behaviors.
Further research is needed to better understand the extent
to which patient beliefs, expectations, and preferences in-
fluence provider–patient communication, shared decision
making, greater achievement of risk-factor reduction, and
prevention of CVD. This is particularly needed in under-
served minority groups that suffer a disproportionate CV
risk burden. For many patients, perhaps particularly for
those living in poverty with social, environmental, and
behavioral burdens, daily burdens are of greater priority than
preventive CV health care and are obstacles to health
improvement. Consideration of an individual’s environmen-
tal, social, and cultural context is paramount in addressing
and overcoming individual barriers to risk reduction.
SUMMARY
At the beginning of the 21st century, the record in the fight
against CVD has been mixed. Tremendous gains have been
seen in our understanding of the etiology, treatment, and
prevention of CVD. There has been modest success in
implementing preventive risk-reduction therapies. For in-
598 Benjamin and Smith et al. JACC Vol. 40, No. 4, 2002
Task Force #1—Magnitude of the Prevention Problem August 21, 2002:579–651
stance, the prevalence of smoking has declined, and signif-
icant gains have been made in the development and the
implementation of effective secondary prevention measures.
However, in the face of these successes, disturbing trends
have emerged. Obesity and diabetes mellitus are increasing
in epidemic proportions, and gains in smoking cessation and
physical activity appear to be stagnating. Furthermore, as
affluent Americans are receiving increasingly better CV care
and enjoying a longer life span free of CVD, the ethnic and
economic disparities are widening. In addition, in all eco-
nomic strata, ethnicities, and regions, the gap between
primordial, primary, and secondary CVD prevention goals
and the reality of implementation is enormous.
Despite the emergence of these new challenges, unprec-
edented opportunities exist for CVD prevention. Given the
breadth and richness of the accumulated knowledge base,
society is now in a position to envision the ultimate control
of CVD. The fundamental causes of atherosclerosis, hyper-
tension, and diabetes are increasingly understood; highly
effective preventive interventions are known; and many
therapeutic modalities are available to treat patients with
established disease. Based on an examination of the last four
decades, when overall CVD death rates in the U.S. have
declined an average of 2.5% per year, a future date can be
projected when mortality from CVD will be markedly lower
assuming that the current rate of decline continues (Table
1). Furthermore, based on accumulated epidemiological
experience worldwide, a population lifestyle can be specified
that would be associated with very low or absent rates of
atherosclerosis. Thus, eliminating smoking, reducing total
fat to less than 25% to 30% of calories and saturated fat to
less than 7%, reducing dietary salt to less than 3 g/day,
eliminating obesity, encouraging moderate daily physical
activity, and treating high BP and high cholesterol with
available drugs can confidently be predicted to reduce CHD
rates to very low levels, perhaps less than 10% to 15% of all
deaths. That level of mortality should qualify as an achiev-
able goal over the next 20 years. Achieving a lifestyle that
promotes that level of CV health for all members of society
remains an enormous practical challenge in political terms,
requiring fundamental changes in food production and
marketing, community design, work routines, and patterns
of care delivery. Nonetheless, attempts should continue to
communicate more forcefully the enormous success of the
scientific enterprise in its evolution of the position that
CVD would now be controlled if existing knowledge were
put into practice.
The cardiology community thus has a unique obligation
to promote CV health, particularly in the medical setting.
The cardiology community must partner with others to
remove obstacles to disease prevention in the health care
environment, including the community, the medical setting,
and patients. To achieve significant reductions in CVD will
require the following: 1) intensive research into the attitu-
dinal, knowledge, and organizational barriers that decrease
adherence to known efficacious preventive strategies; 2) the
Figure 5. CVD prevention–conceptual framework. CVD  cardiovascular disease. Modified with permission from Green LW, et al. Health promotion
planning: an educational and environmental approach. 2nd ed. Mountain View, CA: Mayfield Publishing Company, 1991:150.
Table 1. Coronary Heart Disease and Stroke Mortality by Race
and Ethnicity—United States 1998
Heart Disease Stroke
Non-Hispanic White 182.8 60.3
Black 186.8 81.6
Native American 112.7 39.2
Asian 100.1 54.6
Hispanic 124.2 40.0
Source: National Center for Health Statistics—Standardized to 2000.
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funding of commitments to research and to the delivery of
preventive services; 3) policy changes to guarantee access to
care by all members of society, to promote healthy lifestyles
and environments in the community, and to facilitate a shift
in emphasis toward prevention by health care providers; and
4) changes in clinical practice to emphasize prevention.
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Task Force #2—The Cost of Prevention:
Can We Afford It? Can We Afford Not To Do It?
Harlan M. Krumholz, MD, FACC, Co-Chair, William S. Weintraub, MD, FACC, Co-Chair,
W. David Bradford, PHD, Paul A. Heidenreich, MD, MS, FACC,
Daniel B. Mark, MD, MPH, FACC, A. David Paltiel, MBA, PHD
The development of many strategies for the prevention of
cardiovascular disease (CVD) presents an important policy
question for society: do the benefits of these programs and
interventions justify the investment in them? Preventive
strategies may provide attractive opportunities to avoid or
defer disease and disability, but they may have substantial
costs and must often be applied to many subjects in order to
reach the few in the group who will benefit the most.
Whether and how limited health care dollars should be
allocated to these activities is therefore an important area of
inquiry for health care policy makers and practitioners.
Economic considerations now dominate the health care
policy debate. Purchasers of health care have limited re-
sources and thus must determine the “value” of the services
of their spending decisions. The expanding array of CVD
preventive options, including novel markers of risk, new
imaging modalities, and innovative interventions, has drawn
particular attention as the pressure on health care budgets
increases. Currently, the U.S. uses almost 14% of its gross
domestic product (GDP) on health care reaching more than
$1.5 trillion per year (1). Health care inflation, initially
stabilizing in the mid-1990s, is again increasing at a more
rapid rate than the general consumer price index (2), leading
to marked increases in health insurance premiums (3). In
this economic environment, the failure of cardiologists to
take economic issues seriously may place their patients at a
distinct disadvantage in competing for scarce health care
resources with patients who have, or are at risk for, other
disease. Arguments in favor of the allocation of resources for
CVD prevention will increasingly need to be supported by
evidence of the value of the investment. Guideline commit-
tees need to consider the economic implications of their
recommendations and appeal not only to evidence of the
effectiveness of specific strategies but also to their value from
a societal perspective. Policy will not be based on this
information alone, but the information will be necessary to
persuade care purchasers of the worthiness of these activi-
ties.
In this discussion, what is currently known about the
value of selected preventive strategies for atherosclerotic
disease is reviewed, referring to the extra dollars spent on a
given program or intervention to produce extra health
benefits. In this context, what extra benefits these strategies
are producing, what they cost to produce these benefits, and
the ratio of the cost to the benefit are examined. Contro-
versies in this field that relate to valuing health care are also
considered. A proposal for an integrated policy designed to
determine the value of CVD prevention is presented in
conclusion.
COST-EFFECTIVENESS ANALYSIS OF
PREVENTIVE STRATEGIES: BRIEF OVERVIEW
A challenge for a society with finite resources is to deter-
mine which interventions and programs have the most
value. An approach to measuring value is to determine
which interventions yield the best extra or incremental
benefits (e.g., most quality-adjusted life-years [QALYs],
most years free from pain, and longest life in years) relative
to the extra resources (costs) required to produce those
benefits. Cost-effectiveness analysis is the most widely used
approach for the economic analysis of medical strategies and
interventions. It provides a way to compare incremental
costs and benefits, typically summarized as a cost-
effectiveness ratio (cost per unit of health outcomes
achieved).
Interventions that improve outcomes and decrease, or do
not change, costs are ideal yet all too rare. Strategies that
increase costs and worsen outcomes are easy to reject. The
challenge involves those strategies that improve outcomes
but require extra resources. Cost-effectiveness analysis pro-
vides an approach for the ranking of the relative value of
these options. When common definitions of health out-
comes are employed, it is possible to compare the opportu-
nity costs of various choices. “Opportunity costs” are the
value forgone by devoting resources to a given activity rather
than to their best alternative use.
For these ratios, no specific value ensures that a designa-
tion will be “cost-effective”—the distinction is relative and
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